Clinical Trial: ALLIANCE A051902

ALLIANCE A051902

Status: Open

NCT#04803201

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

A051902 accrual to older patient cohort (age >60) is reopened to accrual, effective September 20, 2024.

A051902 is open to accrual to the Randomized Phase II Safety check portion of the study, effective September 18. 2023.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Available Clinical Trials

Clinical Trial: ALLIANCE A051902

ALLIANCE A051902

NCT#04803201

Navigation

About Us

Contact Us